Evidence map›Paper›PMID 39204061›Full record

ReviewVaccines2024

Using Regular High-Quality Serosurveys to Identify and Close National Immunity Gaps-Measles and Rubella Elimination in Japan.

Tomimasa Sunagawa, Yusuke Kobayashi, Yoshihiro Takashima, Hajime Kamiya, Tomoe Shimada, Kazutoshi Nakashima, Satoru Arai, Kiyosu Taniguchi, Keiko Tanaka-Taya, Nobuhiko Okabe

Abstract readReview
In one paragraph

Review in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tomimasa SunagawaNational Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Yusuke KobayashiNational Institute of Infectious Diseases, Tokyo 162-8640, Japan.ORCID 0000-0002-4541-8318
Yoshihiro TakashimaOsaka University Center for Infectious Disease Education and Research, Osaka 565-0871, Japan.ORCID 0000-0001-8319-4653
Hajime KamiyaGraduate School of Medicine, Mie University, Tsu 514-8507, Japan.
Tomoe ShimadaNational Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Kazutoshi NakashimaDepartment of Health Science, Faculty of Sports and Health Science, Daito Bunka University, Tokyo 175-8571, Japan.
Satoru AraiNational Institute of Infectious Diseases, Tokyo 162-8640, Japan.ORCID 0000-0001-5865-0717
Kiyosu TaniguchiDepartment of Pediatrics, Mie National Hospital, National Hospital Organization, Tsu 514-0125, Japan.ORCID 0000-0003-4584-6168
Keiko Tanaka-TayaKanagawa Prefectural Institute of Public Health, Kanagawa 253-0087, Japan.
Nobuhiko OkabeKawasaki City Institute for Public Health, Kanagawa 210-0821, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Japan, periodic measles outbreaks occurred mainly among young children under the routine immunization program with one dose of the measles-containing vaccine (MCV). A second dose of MCV was introduced in 2006. During a nationwide measles resurgence in 2007-2008, the most affected age group was teenagers. The national serological surveillance for vaccine-preventable diseases made it clear that there was a measles immunity gap among teenagers who had not received a second dose of MCV. To fill this immunity gap, nationwide non-selective supplementary immunization activities (SIAs) were carried out as a five-year program from April 2008 to March 2013 by providing an opportunity to be vaccinated with the measles and rubella vaccine during the first year of junior high school (12-13 years old) and the last year of high school (17-18 years old). The SIA was conducted with the strong involvement of local governments in charge of vaccination delivery and collaboration between the health and education sectors. Japan was verified as achieving measles elimination in 2015 and this has been sustained to date. The challenge of rubella elimination following a similar strategy of a serological diagnosis of an immunity gap and targeted vaccination is also discussed.

Indexed as

eliminationimmunity gapsmeaslesrubellaserological surveillanceSIAs

Identifiers

PMID39204061
PMCPMC11360166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.